Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Sigurdis Haraldsdottir"'
Autor:
Diego A.S. Toesca, Jeremy P. Harris, Daniel T. Chang, Chiaojung Jillian Tsai, Julie L. Koenig, Sigurdis Haraldsdottir, Erqi L. Pollom, Albert Lin
Publikováno v:
American Journal of Clinical Oncology. 42:573-580
Randomized control trials and population-based studies do not demonstrate a definitive benefit for adjuvant chemotherapy (ACT) in stage II colon cancer (CC). Tumor sidedness and microsatellite instability (MSI) status may predict response to ACT, but
Publikováno v:
Current Colorectal Cancer Reports. 13:419-428
Resection of metastatic colorectal cancer (mCRC) can dramatically improve overall survival (OS), particularly in patients with isolated colorectal liver metastases (CLMs). In this review, we summarize recent findings and studies addressing chemothera
Autor:
Adalsteinn Gunnlaugsson, Thorvardur R. Halfdanarson, Agnes Smaradottir, Sigurdis Haraldsdottir, Hulda M Einarsdottir
Publikováno v:
Læknablaðið. 2014:75-82
Colorectal cancer is the third most common cancer in the Western hemisphere and the incidence increases with increasing age. Most colorectal cancers are localized with or without lymph node metastases. Up to 20% of patients present with metastatic di
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 5 (2013)
Colorectal cancer is the third most common cancer in the Western population and has a 5-year overall survival of 5–10% when metastatic. Approximately 30% of the patients with metastatic colorectal cancer have limited disease apparently isolated to
Publikováno v:
Clinical Investigation. 2:1109-1122
Metastatic colorectal cancer is the second leading cause of cancer-related death in the Western population. New therapies have been developed at a rapid pace in the past 15 years with six new agents being approved since 1996, with the most recent add
Publikováno v:
Thyroid Cancer ISBN: 9781493933129
Chemotherapy has been used as a single-modality treatment or as part of combined-modality therapy in metastatic or locally advanced thyroid cancer when other conventional treatments (e.g., surgery and radiation therapy) have failed. Recent developmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b8f76ac5d6399f371a077c474df8962
https://doi.org/10.1007/978-1-4939-3314-3_64
https://doi.org/10.1007/978-1-4939-3314-3_64
Publikováno v:
Thyroid Cancer ISBN: 9781493933129
Anaplastic thyroid cancers (ATC) account for roughly 2.2 % of all thyroid cancers in the USA (Hossain et al. J Clin Oncol 28(15s):abstr 5588, 2010) and are believed to arise from differentiated thyroid cancers (DTC) via the accumulation of genetic ab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14679e5033d28f7819170b5971d26843
https://doi.org/10.1007/978-1-4939-3314-3_99
https://doi.org/10.1007/978-1-4939-3314-3_99
Publikováno v:
Thyroid Cancer ISBN: 9781493933129
Molecular studies have led to an increased appreciation for the heterogeneity of thyroid neoplasms, and recent work has outlined the importance of hereditary predisposition, somatic mutation, epigenetic modulation, and tumor microenvironment and thei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::928406851700def12bd97f3a3bc26f84
https://doi.org/10.1007/978-1-4939-3314-3_105
https://doi.org/10.1007/978-1-4939-3314-3_105
Publikováno v:
Journal of Clinical Oncology. 30:e14178-e14178
e14178 Background: Panitumumab (Pmab) is a fully humanized monoclonal IgG-2 antibody against epidermal growth factor receptor (EGFR). It was approved by the FDA in September 2006 as 3rd line therapy in metastatic colorectal cancer with disease progre